abrdn plc Has $17.63 Million Holdings in DaVita Inc. (NYSE:DVA)

abrdn plc boosted its holdings in shares of DaVita Inc. (NYSE:DVA) by 17.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 168,316 shares of the company’s stock after purchasing an additional 24,966 shares during the period. abrdn plc owned 0.18% of DaVita worth $17,633,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Federated Hermes Inc. increased its stake in shares of DaVita by 6,158.3% in the fourth quarter. Federated Hermes Inc. now owns 77,979 shares of the company’s stock valued at $8,169,000 after buying an additional 76,733 shares in the last quarter. Daiwa Securities Group Inc. increased its position in DaVita by 3.7% in the 4th quarter. Daiwa Securities Group Inc. now owns 4,802 shares of the company’s stock valued at $503,000 after acquiring an additional 171 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of DaVita by 28.5% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 95,657 shares of the company’s stock worth $10,021,000 after acquiring an additional 21,205 shares during the last quarter. Everence Capital Management Inc. acquired a new position in shares of DaVita during the fourth quarter worth approximately $393,000. Finally, LifePlan Financial LLC bought a new stake in shares of DaVita during the fourth quarter valued at approximately $224,000. Institutional investors own 90.12% of the company’s stock.

Analyst Ratings Changes

Several research analysts have issued reports on the company. StockNews.com downgraded DaVita from a “strong-buy” rating to a “buy” rating in a report on Tuesday, April 16th. Truist Financial upped their price target on DaVita from $130.00 to $135.00 and gave the company a “hold” rating in a research note on Tuesday, February 20th. Barclays began coverage on DaVita in a research report on Wednesday, March 6th. They issued an “equal weight” rating and a $133.00 price objective for the company. UBS Group upped their target price on shares of DaVita from $113.00 to $134.00 and gave the company a “buy” rating in a research report on Wednesday, February 14th. Finally, TheStreet upgraded shares of DaVita from a “c+” rating to a “b-” rating in a research report on Wednesday, February 7th. Two research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $118.50.

Insider Activity at DaVita

In other DaVita news, CEO Javier Rodriguez sold 67,603 shares of the firm’s stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $126.11, for a total transaction of $8,525,414.33. Following the sale, the chief executive officer now directly owns 488,697 shares in the company, valued at approximately $61,629,578.67. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other DaVita news, insider James O. Hearty sold 26,164 shares of DaVita stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $119.64, for a total value of $3,130,260.96. Following the sale, the insider now owns 20,264 shares of the company’s stock, valued at approximately $2,424,384.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Javier Rodriguez sold 67,603 shares of the stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $126.11, for a total value of $8,525,414.33. Following the transaction, the chief executive officer now owns 488,697 shares of the company’s stock, valued at $61,629,578.67. The disclosure for this sale can be found here. In the last three months, insiders sold 134,540 shares of company stock worth $16,551,071. 1.40% of the stock is owned by company insiders.

DaVita Stock Down 0.9 %

DaVita stock opened at $132.75 on Thursday. The firm has a market capitalization of $11.64 billion, a price-to-earnings ratio of 17.94, a PEG ratio of 1.19 and a beta of 1.04. The company’s 50 day simple moving average is $131.63 and its 200 day simple moving average is $110.00. The company has a debt-to-equity ratio of 6.65, a current ratio of 1.19 and a quick ratio of 1.13. DaVita Inc. has a fifty-two week low of $71.51 and a fifty-two week high of $141.54.

DaVita (NYSE:DVA) last issued its quarterly earnings data on Tuesday, February 13th. The company reported $1.87 EPS for the quarter, topping the consensus estimate of $1.53 by $0.34. DaVita had a return on equity of 64.42% and a net margin of 5.70%. The business had revenue of $3.15 billion for the quarter, compared to the consensus estimate of $3.01 billion. During the same quarter last year, the business posted $1.11 EPS. The firm’s revenue was up 7.8% compared to the same quarter last year. As a group, sell-side analysts anticipate that DaVita Inc. will post 9.23 EPS for the current year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.